Adenoviral gene transfer of a u-PA receptor-binding plasmin inhibitor and green fluorescent protein: Inhibition of migration and visualization of expression

Thrombosis and Haemostasis

Volumn 84, Issue 3, 2000, Pages 460-467

  Lamfers, M L M ^a   Wijnberg, M J ^a   Grimbergen, J M ^a   Huisman, L G M ^a   Aalders, M C ^a   Cohen, F N B ^a   Verheijen, J H ^a   Van Hinsbergh, V W M ^a   Quax, P H A ^a  

^a TNO   (Netherlands)

Author keywords

Gene therapy; Green fluorescent protein; Plasmin; Plasminogen activators; SMC migration

Indexed keywords

ANTIPLASMIN; APROTININ; GREEN FLUORESCENT PROTEIN; PLASMINOGEN ACTIVATOR; UROKINASE; UROKINASE RECEPTOR;

ADENOVIRUS; ARTERY INTIMA PROLIFERATION; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; DRUG INHIBITION; EXPRESSION VECTOR; GENE THERAPY; GENE TRANSFER; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MIGRATION INHIBITION; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; SMOOTH MUSCLE FIBER;

EID: 0033828107     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614045     Document Type: Article

References (43)

1. The plasminogen system and cell surfaces: Evidence for plasminogen and urokinase receptors on the same cell type
2. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis
3. The urokinase receptor and cell migration
4. Angiogenesis: A paradigm for balanced extracellular proteolysis during cell migration and morphogenesis
5. Regulation and role of urokinase plasminogen activator in vascular remodelling
6. The migration of human smooth muscle cells in vitro is mediated by plasminogen activation and can be inhibited by alpha2-macroglobulin receptor associated protein
7. Contrasting effects of plasminogen activators, urokinase receptor, and LDL receptor-related protein on smooth muscle cell migration and invasion
8. Urokinase and tissue-type plasminogen activator are required for the mitogenic and chemotactic effects of bovine fibroblast growth factor and platelet-derived growth factor-BB for vascular smooth muscle cells
9. The role of plasminogen activation in smooth muscle cell migration after arterial injury
10. Migration of arterial wall cells. Expression of plasminogen activators and inhibitors in injured rat arteries
11. Impaired arterial neointima formation in mice with disruption of the plasminogen gene
12. Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice
13. The growth factor module of urokinase is the binding sequence for its receptor
14. The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases
15. The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants
16. Induction of vascular SMC proliferation by urokinase indicates a novel mechanism of action in vasoproliferative disorders
17. Induction in human osteoblastic cells (SaOS2) of the early response genes fos, jun, and myc by the amino terminal fragment (ATF) of urokinase
18. Growth stimulation of human epidermal cells by urokinase is restricted to the intact active enzyme
19. Inhibition of cell surface receptor-bound plasmin by alpha 2-antiplasmin and alpha 2-macroglobulin
20. Mitogen crosstalk accompanying urokinase receptor expression in stimulated vascular smooth muscle cells
21. Inhibition of neointima formation in cultured human saphenous vein segments by an adenovirus expressing a urokinase receptor-binding plasmin inhibitor
22. Green fluorescent protein: Applications in cell biology
23. Green fluorescent protein as a marker for gene expression
24. Human arterial wall cells and tissues in culture
25. Characterization of 911: A new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors
26. Binding of human urokinase-type plasminogen activator to its receptor - Residues involved in species specificity and binding
27. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
28. Quantitation of urokinase antigen in plasma and culture media by use of an ELISA
29. Comparison of the inhibition of urokinase-type plasminogen activator (u-PA) activity by monoclonal antibodies specific for u-PA as assessed by different assays
30. Pharmacological approaches for the prevention of restenosis after percutaneous coronary intervention
31. Pharmacological approaches to the prevention of restenosis following angioplasty. The search for the Holy Grail? (Part II)
32. Extracellular matrix remodeling by metalloproteinases and plasminogen activators
33. A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification
34. Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor
35. Urokinase plasminogen activator induces smooth muscle cell migration: Key role of growth factor-like domain
36. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity
37. Melanoma cell migration on vitronectin: Regulation by components of the plasminogen activation system
38. Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice
39. Role and localization of urokinase receptor in the formation of new microvascular structures in fibrin matrices
40. Urokinase-type and tissue-type plasminogen activators as growth factors of human fibroblasts
41. Mitogenic effects of urokinase on melanoma cells are independent of high affinity binding to the urokinase receptor
42. Divergent effects of tissue inhibitor of metalloproteinase- 1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro - TIMP-3 promotes apoptosis
43. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3